3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
NET
1
Head & Neck
1
Gastrointestinal
1
Endocrine
1
Conditions
Thyroid Neoplasms
1
Thyroid Diseases
1
Thyroid Cancer, Papillary
1
Thoracic Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Neuroendocrine Tumors
1
Neuroectodermal Tumors
1
Neoplasms, Nerve Tissue
1
Neoplasms, Glandular and Epithelial
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Multiple Endocrine Neoplasia Type 2a
1
Lung Neoplasms
1
Lung Diseases
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Endocrine System Diseases
1
Endocrine Gland Neoplasms
1
Digestive System Neoplasms
1
Digestive System Diseases
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Colonic Diseases
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Gemcitabine
109
Paclitaxel
92
Carboplatin
79
pembrolizumab
75
Bevacizumab
75
Surveys and Questionnaires
70
Docetaxel
69
Cisplatin
67
Nivolumab
48
Exercise
48
Capecitabine
48
Cyclophosphamide
47
Sorafenib
43
Fluorouracil
43
Irinotecan
42
Pemetrexed
37
Albumin-Bound Paclitaxel
35
Radiotherapy
34
Dexamethasone
34
Blood Specimen Collection
34
Oxaliplatin
31
Leucovorin
31
Erlotinib Hydrochloride
31
trametinib
30
130-nm albumin-bound paclitaxel
29
Cetuximab
28
Therapeutics
26
Ipilimumab
26
Standard of Care
25
Methods
25
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Neoplasms
×
pralsetinib
×
Clear all
NCT03037385
2025-05-31
ARROW
Hoffmann-La Roche
Phase 1/2
Completed
590 enrolled
58 charts
3 FDA